It's still unknown what drug we were paired with. If it was done with dostarlimab and a separate arm of just leronlimab it should make GSK take notice. They'd definitely want to make any offer before data was released. If one arm wasn't done with just leronlimab they may assume the effect on PD-1/PD-L1 was solely due to their drug.